QT Vascular enrols first patients for Chocolate Touch study
Singapore
CATALIST-LISTED healthcare company QT Vascular has announced that it has enrolled the first 11 patients in its First-In-Human (FIH) study of its novel Chocolate Touch PTCA (Coronary Drug Coated Chocolate) in the Dominican Republic.
In a filing to the Singapore Exchange on Tuesday, the group said it is working closely with local and United States physicians on the study, which will evaluate the clinical utility of the Chocolate Touch PTCA for the treatment of de novo coronary lesions.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
HCA beats first-quarter profit estimates on higher patient admissions
F&B operator YKGI to exclusively operate Chicha San Chen in Macau for next eight years
LMIRT Q1 net property income dips 3.1% to S$30 million on higher expenses
Exxon misses on Q1 profit despite big gains in Guyana
US FDA approves Pfizer’s gene therapy for rare bleeding disorder
Chevron's quarterly profit beats estimates